Movement Alert｜IMPACT THERAP-B Falls 8.05% in Regular Trading, Profit-Taking After Recent Surge Compounded by Biotech Sector Weakness

Market Focus09-24

On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven by positive regulatory news.

The stock had surged over 27% on September 21 — with intraday gains reaching as high as 58% to HK$20.56 — after the company and its partner Pharmanovia announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Sepalna (senaparib) as a maintenance treatment for advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. Following the rapid rally, profit-taking pressure intensified significantly.

Simultaneously, the broader biotechnology sector came under selling pressure, with peers including REMEGEN down 5.71%, 3SBIO down 3.76%, AKESO down 3.64%, INNOVENT BIO down 3.63%, and BEONE MEDICINES down 1.56%, creating a drag on individual names across the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196903490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196903490","market":"hk","top_or_hot":-1,"title":"Movement Alert｜IMPACT THERAP-B Falls 8.05% in Regular Trading, Profit-Taking After Recent Surge Compounded by Biotech Sector Weakness","media":"Market Focus","content":"<p><p>On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven by positive regulatory news.</p><p>The stock had surged over 27% on September 21 — with intraday gains reaching as high as 58% to HK$20.56 — after the company and its partner Pharmanovia announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Sepalna (senaparib) as a maintenance treatment for advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. Following the rapid rally, profit-taking pressure intensified significantly.</p><p>Simultaneously, the broader biotechnology sector came under selling pressure, with peers including REMEGEN down 5.71%, 3SBIO down 3.76%, AKESO down 3.64%, INNOVENT BIO down 3.63%, and BEONE MEDICINES down 1.56%, creating a drag on individual names across the sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜IMPACT THERAP-B Falls 8.05% in Regular Trading, Profit-Taking After Recent Surge Compounded by Biotech Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜IMPACT THERAP-B Falls 8.05% in Regular Trading, Profit-Taking After Recent Surge Compounded by Biotech Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven by positive regulatory news.</p><p>The stock had surged over 27% on September 21 — with intraday gains reaching as high as 58% to HK$20.56 — after the company and its partner Pharmanovia announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Sepalna (senaparib) as a maintenance treatment for advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. Following the rapid rally, profit-taking pressure intensified significantly.</p><p>Simultaneously, the broader biotechnology sector came under selling pressure, with peers including REMEGEN down 5.71%, 3SBIO down 3.76%, AKESO down 3.64%, INNOVENT BIO down 3.63%, and BEONE MEDICINES down 1.56%, creating a drag on individual names across the sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1196903490","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196903490","pubTimestamp":1790215962,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"走势警报|IMPACT THERAP-B 在常规交易中下跌 8.05%，在生物技术板块疲软加剧了近期飙升后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven by positive regulatory news.The stock had surged over 27% on September 21 — with intraday gains reaching as high as 58% to HK$20.56 — after the company and its partner Pharmanovia announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Sepalna (senaparib) as a maintenance treatment for advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. Following the rapid rally, profit-taking pressure intensified significantly.Simultaneously, the broader biotechnology sector came under selling pressure, with peers including REMEGEN down 5.71%, 3SBIO down 3.76%, AKESO down 3.64%, INNOVENT BIO down 3.63%, and BEONE MEDICINES down 1.56%, creating a drag on individual names across the sector.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196903490","isCrawlerRequest":true}